Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

A cure for genetic heart conditions could reach trials in only 5 years, and it “rewrites” DNA. Experts explain the potential ...

Agios Pharmaceuticals gears up for a pivotal 2025 with key PYRUKYND milestones, including FDA decisions for thalassemia.

The choice of keeping your babys cord blood is a very personal one but it is also one of the few times where parents must be ...

Gene Therapy Market Gene therapy market surges on breakthroughs in genome editing, rising chronic & genetic disease cases, regulatory appro ...

Oregon will initially focus on providing lower-cost therapies for people living with sickle cell disease, a genetic blood ...

The Centers for Medicare & Medicaid Services (“CMS”) recently released two proposed updates to Medicare payment rules that, if implemented, could ...

After decades of excruciating pain, a breakthrough sickle cell disease treatment made all the difference for one patient.

"We haven't yet achieved the mission of the NIH, which is research that improves the health and longevity of the American people," Jay Bhattacharya said.

AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1 at AGC Inc.’s Yokohama Technical Center.

New tools and delivery vehicles for CRISPR are only truly beneficial if we can simultaneously improve the affordability and access.

Fulcrum Therapeutics reports promising late-stage data for sickle cell drug pociredir, with notable hemoglobin improvements.